Consonance Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Consonance Capital Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,155,793	Closed	-$11M	–	32
2018 Q4	$11M	Sell	1,155,793 -1,591,405	-58%	-$20.6M	0.81%	19
2018 Q3	$45.6M	Hold	2,747,198	–	–	2.46%	18
2018 Q2	$44.1M	Buy	2,747,198 +140,600	+5%	+$2.51M	2.84%	16
2018 Q1	$39.9M	Buy	2,606,598 +256,806	+11%	+$4M	3.64%	12
2017 Q4	$36.7M	Buy	2,349,792 +2,248,372	+2,217%	+$30.1M	3.31%	13
2017 Q3	$1.13M	Buy	+101,420	New	+$954K	0.12%	18

Other funds holding STML

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Consonance Capital Management's STML Position: Q1 2019 in Review

Consonance Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2019, closing a stake of 1,155,793 shares — an estimated $11M sold.

Consonance Capital Management first reported a position in STML in Q3 2017 and held it in 6 quarters. The position peaked at $45.6M in Q3 2018. 98 funds tracked by Wall St. Rank hold STML as of Q1 2019.

Consonance Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Consonance Capital Management sold 1,155,793 Stemline Therapeutics, Inc. shares in Q1 2019, an estimated $11M.
Consonance Capital Management first reported a position in Stemline Therapeutics, Inc. in Q3 2017 and held it in 6 quarters.
Consonance Capital Management's Stemline Therapeutics, Inc. position peaked at $45.6M in Q3 2018.
98 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2019.

Based on Consonance Capital Management's 13F filing for Q1 2019, filed 15 May 2019.